. Therapeutic hypercapnia prevents chronic hypoxia-induced pulmonary hypertension in the newborn rat. Am J Physiol Lung Cell Mol Physiol 291: L912-L922, 2006. First published July 7, 2006 doi:10.1152/ajplung.00480.2005.-Induction of hypercapnia by breathing high concentrations of carbon dioxide (CO2) may have beneficial effects on the pulmonary circulation. We tested the hypothesis that exposure to CO2 would protect against chronic pulmonary hypertension in newborn rats. Atmospheric CO2 was maintained at Ͻ0.5% (normocapnia), 5.5%, or 10% during exposure from birth for 14 days to normoxia (21% O2) or moderate hypoxia (13% O2). Pulmonary vascular and hemodynamic abnormalities in animals exposed to chronic hypoxia included increased pulmonary arterial resistance, right ventricular hypertrophy and dysfunction, medial thickening of pulmonary resistance arteries, and distal arterial muscularization. Exposure to 10% CO2 (but not to 5.5% CO2) significantly attenuated pulmonary vascular remodeling and increased pulmonary arterial resistance in hypoxia-exposed animals (P Ͻ 0.05), whereas both concentrations of CO2 normalized right ventricular performance. Exposure to 10% CO2 attenuated increased oxidant stress induced by hypoxia, as quantified by 8-isoprostane content in the lung, and prevented upregulation of endothelin-1, a critical mediator of pulmonary vascular remodeling. We conclude that hypercapnic acidosis has beneficial effects on pulmonary hypertension and vascular remodeling induced by chronic hypoxia, which we speculate derives from antioxidant properties of CO2 on the lung and consequent modulating effects on the endothelin pathway. carbon dioxide; endothelin; oxidant stress; 8-isoprostane; echocardiography PULMONARY HYPERTENSION, characterized by increased pulmonary artery resistance and pressure, is a common complication of sick newborn infants that carries a high mortality and is associated with considerable long-term morbidity in survivors (43,59,60). Studies suggest that the newborn is uniquely susceptible to remodeling of pulmonary resistance arteries (49). Vascular remodeling contributes to increased resistance (15), may limit the effectiveness of vasodilator therapies (15,32), and in the newborn appears to contribute to inhibition of lung growth and alveolar development (33,45,46,57). Reversal of pathological changes in the newborn pulmonary vascular bed is also more likely to be delayed and incomplete (29,31,49), leading to an increased susceptibility to the development of more severe pulmonary hypertension in later life (10, 17). Thus therapies aimed at preventing or ameliorating vascular remodeling in the newborn have great potential to improve mortality and long-term outcome.A major pathological role for reactive oxygen species (ROS) in pulmonary hypertension is likely, as evidenced by observational studies showing increased oxidant stress in the lungs of adult humans with idiopathic pulmonary arterial hypertension (6, 13) and by the reported efficacy of various antioxidant interventions in the pr...